Ciltacabtagene Autoleucel for the Treatment of Relapsed/Refractory Multiple Myeloma: Efficacy, Safety, and Place in Therapy

Ciltacabtagene Autoleucel for the Treatment of Relapsed/Refractory Multiple Myeloma: Efficacy, Safety, and Place in Therapy

Utkarsh Goel,1 Saurabh Zanwar,2 Andrew John Cowan,3 Rahul Banerjee,3 Jack Khouri,4 Danai Dima3 1Department of Internal Medicine, Cleveland Clinic, Cleveland, OH, USA; 2Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA; 3University of Washington, Fred Hutchinson Cancer C...

Full description

Saved in:
Bibliographic Details
Main Authors: Goel U, Zanwar S, Cowan AJ, Banerjee R, Khouri J, Dima D
Format: Article
Language:English
Published: Dove Medical Press 2025-02-01
Series:Cancer Management and Research
Subjects:
multiple myeloma
ciltacabtagene autoleucel
car t
chimeric antigen receptor t cell therapy
relapsed/refractory multiple myeloma.
Online Access:https://www.dovepress.com/ciltacabtagene-autoleucel-for-the-treatment-of-relapsedrefractory-mult-peer-reviewed-fulltext-article-CMAR
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.dovepress.com/ciltacabtagene-autoleucel-for-the-treatment-of-relapsedrefractory-mult-peer-reviewed-fulltext-article-CMAR

Similar Items